Form 8-K - Current report:
SEC Accession No. 0001683168-25-001174
Filing Date
2025-02-21
Accepted
2025-02-21 17:00:08
Documents
15
Period of Report
2025-02-19
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT cns_8k.htm   iXBRL 8-K 86877
2 PRESS RELEASE cns_ex9901.htm EX-99.1 8058
6 GRAPHIC image_001.jpg GRAPHIC 8980
  Complete submission text file 0001683168-25-001174.txt   289860

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cnsp-20250219.xsd EX-101.SCH 3018
4 XBRL LABEL FILE cnsp-20250219_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE cnsp-20250219_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT cns_8k_htm.xml XML 3802
Mailing Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027
Business Address 2100 WEST LOOP SOUTH SUITE 900 HOUSTON TX 77027 1-800-946-9185
CNS Pharmaceuticals, Inc. (Filer) CIK: 0001729427 (see all company filings)

EIN.: 822318545 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39126 | Film No.: 25652874
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)